The supplements brand behind a breakout year in retail and new category expansion introduces its most advanced ingredient innovation yet, and gives the pet trade a first look at its new visual identity CHEYENNE, Wyo., Sept. 18, 2026 /PRNewswire/ -- Wuffes, the science-led dog supplement brand that has served more than 1.3 million dog parents, today announces the launch of its Dental Powder supplement range. Powered by SuperYolk™ IgY Technology, a proprietary ingredient exclusive to Wuffes and th

October 9-12, 2026 | Phoenix, Arizona -- New data spans pharmacotherapy, imaging and diagnostics, and device therapy for patients with cardiomyopathy Continue Reading These trials ... represent some of the most anticipated data in ... medicine for patients with cardiomyopathy this year. Post this The HFSA Annual Scientific Meeting takes place October 9-12, 2026 in Phoenix, Arizona. WASHINGTON, Sept. 18, 2026 /PRNewswire/ -- The Heart Failure Society of America (HFSA) today announced the Late-Br

Peer-reviewed findings describe reproducible manufacturing, leading-edge genomic quality controls and preclinical evidence supporting clinical development of an autologous iPSC-derived neuron replacement therapy for Parkinson’s disease, now entering Phase 3 SAN DIEGO, Sept. 18, 2026 (GLOBE NEWSWIRE) -- Aspen Neuroscience, Inc., a clinical-stage regenerative medicine biotechnology company developing personalized, autologous cell therapies for Parkinson’s disease (PD), today announced publicati

FORT LAUDERDALE, Fla., Sept. 18, 2026 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (Nasdaq: TCRT) today announced that it has entered into definitive agreements with institutional investors in a registered direct offering for the sale of 380,469 shares of its common stock and pre-funded warrants to purchase up to 386,654 shares of common stock at a price of $1.46 per share, for aggregate gross proceeds of approximately $1,120,000, before deducting placement agent fees and offering expenses.

GENEVA, Sept. 18, 2026 /PRNewswire/ -- China is seeing growing momentum in inbound medical tourism, driven by expanding access to innovative therapies, visa facilitation and the development of internationally oriented healthcare services, Dr. John K. Hsiang, Chairman of Jiahui Health Executive Committee, said at the World Trade Organization (WTO) Public Forum 2026. At the "Health Without Borders" session on "Medical Tourism — Opportunities and Challenges in Services Trade", Dr. Hsiang was the so

Year-to-date bookings of $16.2 million include a combination of fit-for-purpose multi-modal datasets, datasets-plus-license arrangements, and multi-year platform access licenses; a significant portion of these bookings are expected to be delivered during the remainder of the yearMINNEAPOLIS, Sept. 18, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet,” the “Company,” “we,” “us” or “our”), a leading provider of first-party (direct-from-source) regulatory decision-grade,

New data from prospective real-world studies of VRAYLAR showed meaningful improvements in depressive symptoms, functioning and quality of life among adults living with major depressive disorder (MDD) and bipolar I (BP-I) depression These findings provide additional evidence that the benefits observed with VRAYLAR in clinical trials can also be achieved in routine practice, where patients often have more complex treatment needs NORTH CHICAGO, Ill., Sept. 18, 2026 /PRNewswire/ -- AbbVie (NYSE: AB

"Reduce Oncology Trial Delays from Study Start-Up to Patient Recruitment" is an upcoming free webinar hosted by Xtalks, taking place on 7 October at 10:00 am EDT (4:00 pm CEST / EU-Central). The discussion will explore how earlier site engagement, stronger feasibility and effective patient identification can help Sponsors and CROs reduce avoidable delays in complex oncology trials. The featured speakers will discuss site selection, pre-screening and patient identification for biomarker-driven st

SARASOTA, Fla., Sept. 18, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc., (NASDAQ: LABT, the "Company"), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin® class, today announced that it has obtained central and all site Institutional Review Board (IRB) approvals and confirmed clinical trial site readiness to commence its Phase 2a clinical trial evaluating the safety and

COLUMBUS, Ohio, Sept. 18, 2026 /PRNewswire/ -- Andelyn Biosciences ("Andelyn"), a leading, patient-focused cell and gene therapy Contract Development and Manufacturing Organization ("CDMO"), today announced it is now manufacturing FAYUVI™ (rebisufligene etisparvovec-hopf), an FDA-approved gene therapy, for commercial supply at its Columbus, Ohio facility. The announcement follows the U.S. Food and Drug Administration's approval of Ultragenyx Pharmaceutical Inc.'s FAYUVI™ for treating Sanfilippo